These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 37259600)
1. Cost-effectiveness analysis of pembrolizumab in patients with treatment-refractory metastatic colorectal cancer in Japan. Sugiura K; Hiratsuka H; Oshima G; Aiko S Jpn J Clin Oncol; 2023 Jul; 53(8):691-697. PubMed ID: 37259600 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer. Sugiura K; Seo Y; Takahashi T; Tokura H; Ito Y; Tanaka M; Kishida N; Nishi Y; Onishi Y; Aoki H BMC Gastroenterol; 2021 Apr; 21(1):184. PubMed ID: 33879100 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of pembrolizumab in first-line for microsatellite-instability-high or mismatch-repair-deficient metastatic colorectal cancerF. Giuliani J; Mandara M; Mantoan B; Ferrario L; Mangiola D; Napoli G; Muraro M; Fiorica F J Oncol Pharm Pract; 2023 Jun; 29(4):958-961. PubMed ID: 36823960 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States. Aguiar-Ibáñez R; Hardern C; van Hees F; Lee D; Patel A; Chhabra N; Baluni G; Amonkar M; Lai Y; Xu R; Massaad R; Fogelman D J Med Econ; 2022; 25(1):469-480. PubMed ID: 35184650 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. Chu JN; Choi J; Ostvar S; Torchia JA; Reynolds KL; Tramontano A; Gainor JF; Chung DC; Clark JW; Hur C Cancer; 2019 Jan; 125(2):278-289. PubMed ID: 30343509 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer. Thurgar E; Gouldson M; Matthijsse S; Amonkar M; Marinello P; Upadhyay N; Nwankwo C; Aguiar-Ibáñez R J Med Econ; 2021; 24(1):675-688. PubMed ID: 33866938 [TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States. Cho SK; Hay JW; Barzi A Clin Colorectal Cancer; 2018 Dec; 17(4):e751-e761. PubMed ID: 30228027 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer. Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment for mismatch-repair-deficient (dMMR) or microsatellite-instability-high (MSI-H) advanced or metastatic colorectal cancer from the perspective of the Chinese health-care system. Zhu C; Han G; Wu B BMC Health Serv Res; 2023 Oct; 23(1):1083. PubMed ID: 37821934 [TBL] [Abstract][Full Text] [Related]
11. Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer's Perspective. Qu T; Zhang S; Zhong Y; Meng Y; Guo H; Joo S; Enzinger PC Pharmacoeconomics; 2022 Dec; 40(12):1247-1259. PubMed ID: 36241842 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal Cancer. Patel KK; Stein S; Lacy J; O'Hara M; Huntington SF JAMA Netw Open; 2021 Jan; 4(1):e2033441. PubMed ID: 33433598 [TBL] [Abstract][Full Text] [Related]
13. Testing strategies for Lynch syndrome in people with endometrial cancer: systematic reviews and economic evaluation. Stinton C; Jordan M; Fraser H; Auguste P; Court R; Al-Khudairy L; Madan J; Grammatopoulos D; Taylor-Phillips S Health Technol Assess; 2021 Jun; 25(42):1-216. PubMed ID: 34169821 [TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland. Bhadhuri A; Insinga R; Guggisberg P; Panje C; Schwenkglenks M Swiss Med Wkly; 2019 Dec; 149():w20170. PubMed ID: 31880807 [TBL] [Abstract][Full Text] [Related]
15. A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland. Barbier MC; Pardo E; Panje CM; Gautschi O; Lupatsch JE; Eur J Health Econ; 2021 Jul; 22(5):669-677. PubMed ID: 33745093 [TBL] [Abstract][Full Text] [Related]
16. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model. Hoyle M; Crathorne L; Peters J; Jones-Hughes T; Cooper C; Napier M; Tappenden P; Hyde C Health Technol Assess; 2013 Apr; 17(14):1-237. PubMed ID: 23547747 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France. Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer. Liu T; Liu S; Guan S; Tai Y; Jin Y; Dong M J Chemother; 2023 Dec; 35(8):745-752. PubMed ID: 36591729 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer. Aziz MIA; Tan LE; Tan WHG; Toh CK; Loke LPY; Pearce F; Ng K J Med Econ; 2020 Sep; 23(9):952-960. PubMed ID: 32462958 [No Abstract] [Full Text] [Related]
20. Pembrolizumab with or without chemotherapy versus cetuximab plus chemotherapy to treat recurrent or metastatic head and neck squamous cell carcinoma: An updated KEYNOTE-048 based cost-effectiveness analysis. She L; Tian K; Han J; Zuo W; Wang Z; Zhang N Oral Oncol; 2022 Jun; 129():105871. PubMed ID: 35483156 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]